CN103157095A - Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof - Google Patents
Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof Download PDFInfo
- Publication number
- CN103157095A CN103157095A CN2013100565888A CN201310056588A CN103157095A CN 103157095 A CN103157095 A CN 103157095A CN 2013100565888 A CN2013100565888 A CN 2013100565888A CN 201310056588 A CN201310056588 A CN 201310056588A CN 103157095 A CN103157095 A CN 103157095A
- Authority
- CN
- China
- Prior art keywords
- gram
- semen phaseoli
- dry powder
- phaseoli vulgaris
- stachyose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses kidney bean phytolectin applications in preparation of human drugs and a drug composition, and belongs to the technical field of drugs. Kidney bean phytolectins are used as active components for preparing drugs used for adding lactobacillus amounts in woman vaginas. The drug composition adopts the kidney bean phytolectins, tremella polysaccharide, stachyose or/and raffinose and bletilla gum, or added scutellaria, Hollygreen Barberry and matrine extraction as the active components. The drug composition comprises relative weight parts of that 0.5-1.0 part of the kidney bean phytolectins, 1.5-3.0 parts of the tremella polysaccharide, 0.2-2.0 parts of the stachyose or/and raffinose, 0.2-0.5 part of the bletilla gum and 1.0-3.0 parts of the extraction of one kind or more than one kind of scutellaria dry powder, Hollygreen Barberry dry powder and matrine dry powder. The kidney bean phytolectin applications in preparation of people use drugs and the drug composition can be water-soluble complex liquid and is best to be gel, and also can be solid dosage forms such as suppository, disintegrating tablets and the like which are drug dosage forms suitable for external uses. Compared with the prior art, obtained products do not need to be preserved in a low temperature and is long in storage time and convenient to use.
Description
Technical field
The present invention behaves and uses technical field of pharmaceuticals.
Background technology
Parasitize the intravaginal micropopulation of healthy women and mainly contain antibacterial, fungus, protozoon and virus.They are mainly dwelt in the mucosa gauffer of vagina and fornix section, are secondly cervix uteri.The main permanent bacterium of intravaginal has lactobacillus, staphylococcus epidermidis, escherichia coli, corynebacterium, B family streptococcus, streptococcus faecalis, mycoplasma, Candida albicans, dyspepsiacoccus and bacteroid etc.Intravaginal multiple normal microflora falls and host, environment between consisted of mutual restriction, mutually coordinated, dynamic microecology in vaginas balance.The microecological balance of vagina all plays an important role to the self purification of keeping it and host's health.When the sharply decline of host due to use broad ectrum antibiotic, ovarian function, the vaginal injury that the factors such as surgical operation, external force and childbirth cause, the reasons such as excessive use of lonizing radiation and immunosuppressant, cause the habitat of vagina to occur sharply to change, can destroy its microecological balance, cause the dysbacteriosis of vagina.Very easily cause the infectious disease of vagina this moment, the main source that infects is the conditioned pathogen in microecology in vaginas group, as escherichia coli, bacteroid, dyspepsiacoccus, staphylococcus aureus, B family streptococcus, Candida albicans, infusorian and mycoplasma etc.The vaginal dysbacteriosis main manifestations is various types of vaginitiss.
Treatment measure for this type of disease is mainly to use the preparation of antibiotic, metronidazole, estrogen and acidify vagina to kill intravaginal pathogenic microorganism at present, but effect is all undesirable.
Generally record with the method for quantitative and qualitative analysis that in the healthy women vaginal discharge, viable count is 10
2-9/ ml, the ratio of anaerobe and aerobe is 5:1.Wherein lactobacillus is the permanent bacterium most important in the vagina normal flora, that quantity is maximum, and its quantity accounts for more than 95%, can reach 8 * 10
7/ ml.Lactobacillus plays an important role in keeping the microecology in vaginas balance, and it can decompose the glycogen in the vaginal mucosa epithelial cell, produces a certain amount of lactic acid, makes vagina keep sour environment, is conducive to the self purification of vagina.It can improve the immunologic function of body simultaneously, and activating macrophage is kept the anti-infection ability of vagina part.It also has the effect that prevents that the cervix uteri vagina epitheliumization from giving birth in addition.(Wang Lisheng, Pan Lingjia, Zhou Dianyuan. Chinese microecology magazine .1 998,10 (5): 300-302.).Utilize microbial ecological agent that the lactobacillus in the vagina normal microflora makes to obtain effect preferably to prophylactic treatment and the health care of this class illness.At present, the preparation that on the domestic and international market, existing multiple employing lactobacillus is made such as decide monarch and give birth to, lactobacillus capsule etc.But because the viable bacteria body needs to preserve at low temperatures, the resting period is short, for practical application inconvenience, particularly out of town trip etc.
Application number is that 2011101840614 Chinese patent file has been announced " a kind of human body external compound preparation and uses thereof ", and its first inventor is the first inventor of present patent application namely.This compound preparation plays contraception, prevents and treats sexually transmitted disease (STD) and lubricated take phytohemagglutinin (PHA) and tremella polysaccharide as active component, and its effect is not to increase in woman vagina lactobacillus quantity to keep microecological balance.
Summary of the invention
Purpose of the present invention: application and the pharmaceutical composition thereof of Semen Phaseoli Vulgaris phytohemagglutinin in preparation human medicine is provided, Main Function is to increase lactobacillus quantity in woman vagina, keeps microecological balance, and product does not need to preserve at low temperatures, resting period is long, and is easy to use.
The purposes invention is characterised in that the Semen Phaseoli Vulgaris phytohemagglutinin as the medicine of active component for the preparation of lactobacillus quantity in the increase woman vagina.And the weight content of Semen Phaseoli Vulgaris phytohemagglutinin is preferably the one thousandth of medicine gross weight.
Pharmaceutical composition of the present invention is take Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan as active component, relative weight share in compositions between contained above-mentioned active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan; Or take Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan, Radix Scutellariae extract, Radix Berberidis extract, Radix Sophorae Flavescentis extract as active component, relative weight share in compositions between contained above-mentioned active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan, one or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder are the extract of totally 1.0～3.0 parts of gained.Said Semen Phaseoli Vulgaris phytohemagglutinin can be the Semen Phaseoli Vulgaris phytohemagglutinin, can be also the red kidney bean phytohemagglutinin.
The extract of said Radix Scutellariae, Radix Berberidis and Radix Sophorae Flavescentis dry powder gained is the extract of water extraction generation preferably, warm extraction method during these Chinese medicinal plant extracts all adopt when extracting, and namely in leaching process, temperature maintains between 40～60 ℃ all the time.
The dosage form of natural drug composition of the present invention can be water miscible complex liquid, wherein is preferably gel; It can be also the pharmaceutical dosage form that solid dosage forms such as suppository, disintegrating tablet etc. are suitable for external.
Natural drug composition of the present invention is mainly used in increasing lactobacillus quantity in woman vagina, but also can be used for the control of other illness of human body, as the treatment of wound etc.
Natural drug composition coagulant liquid of the present invention is characterised in that and contains following component in the 100ml coagulant liquid:
Semen Phaseoli Vulgaris phytohemagglutinin 0.5～1.0 gram,
Tremella polysaccharide 1.5～3.0 grams,
Stachyose is or/and cottonseed sugar 0.5～2.0 gram,
Bletilla glucomannan 0.2～0.5 gram,
NaCl 0.8～0.9 gram,
The pH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically;
Or contain following component in the 100ml coagulant liquid:
Semen Phaseoli Vulgaris phytohemagglutinin 0.5～1.0 gram,
Tremella polysaccharide 1.5～3.0 grams,
Stachyose is or/and cottonseed sugar 0.5～2.0 gram,
Bletilla glucomannan 0.2～0.5 gram,
One or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder are water extract of totally 1.0～3.0 gram gained,
NaCl 0.8～0.9 gram,
The pH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically.
Said Semen Phaseoli Vulgaris phytohemagglutinin can be the Semen Phaseoli Vulgaris phytohemagglutinin, can be also the red kidney bean phytohemagglutinin.
Medicaments compound is the pathological state for body, emphasizes organic cooperation of each component and consumption, carries out multiple location, many target spots, multipath comprehensive adjustment, thereby the poised state of recovery body.
Natural drug composition emphasis of the present invention is for the lactobacillus in close relations with women's health, employing is crucial composition from Semen Phaseoli Vulgaris phytohemagglutinin and the oligosaccharide (stachyose is or/and cottonseed sugar) of Semen Phaseoli Vulgaris separation and Extraction, add and join the active ingredient that other extracts from natural product or Chinese herbal medicine, prepare to become and have the vagina of promotion lactobacillus growth, inhibition and kill harmful microorganism comprise antibacterial, the preparation of the effects such as fungus and virus, and additional natural estrogen, protect from infection, repair wound, final realization recovers take lactobacillus as main naturalness.Prove that through practical application this product is to the BV(bacterial vaginosis), the VVC(VVC), the BP(bowenoid papulosis), the HPV(human papillomavirus) and HIV virus all have and suppress and kill function.Product of the present invention optionally promotes one or more probiotics metabolism and breeding, advances the component of host health except containing stachyose and cottonseed sugar etc., also contain phytohemagglutinin, they have obvious facilitation to lactobacillus and Bacillus bifidus breeding.Therefore, product of the present invention is a kind of novel, carries simultaneously the compound formulation of the PHA of probiotic bacteria " grain ", oligosaccharide and breeding (division) promoter, and its action effect is much more obvious than independent prebiotics.
Add oligosaccharide (stachyose is or/and cottonseed sugar) and Bletilla glucomannan, its objective is the repair ability that strengthens natural drug composition and in conjunction with the ability of skin and mucosa; In addition, Bletilla glucomannan itself also has certain bacteriostasis.
Natural drug composition coagulant liquid of the present invention can use like this: under normal circumstances, add water with the coagulant liquid that does not contain Radix Scutellariae, Radix Berberidis and Radix Sophorae Flavescentis composition (being called for short coagulant liquid A) and do the daily cleaning nursing; First use coagulant liquid A when disease occurring, when symptom is heavier or use after coagulant liquid A 48h symptom can use the coagulant liquid (being called for short coagulant liquid B) that contains Radix Scutellariae, Radix Berberidis and Radix Sophorae Flavescentis composition when alleviating.In experiment below and embodiment, Semen Phaseoli Vulgaris used or red kidney bean phytohemagglutinin are patent applicant's laboratory and extract from Semen Phaseoli Vulgaris that produce in Yunnan and red kidney bean.
The little ecology of product of the present invention is kept and the principle that increases lactobacillus quantity is:
1. the pH of solution is 4.0～4.5, great majority is caused the microorganism of BV has inhibitory action, and this pH value is fit to the growth of lactobacillus;
2. phytohemagglutinin is a kind of mitogen, and we find, the Semen Phaseoli Vulgaris phytohemagglutinin can promote lactobacillus growth under above-mentioned formula concentration;
3. also contain oligosaccharide (stachyose and cottonseed sugar) in solution, like this, as the nutrient substance of lactobacillus and lactobacillus is played the effect of nutritional support;
4. also contain estrogen Semen Phaseoli Vulgaris isoflavone in Semen Phaseoli Vulgaris phytohemagglutinin extracting solution, relevant studies show that both domestic and external, senile vaginitis patients uses estrogen can reverse the atrophy change of vaginal wall and relief of symptoms, the elasticity of the estrogenic additional thickness that increases vagina epithelium, vaginal wall, reduce vaginal pH, recovered the self purification of vagina;
5. phytohemagglutinin can stimulate lymphocyte to produce interferon and interleukin.
Beneficial effect of the present invention: compared to the prior art, products obtained therefrom does not need to preserve at low temperatures, and the resting period is long, and is easy to use.
Description of drawings
Fig. 1 shows that the Semen Phaseoli Vulgaris PHA of variable concentrations is on the microphotograph of lactobacter growth impact.
Fig. 2 represents that three test group are to the effect of scalding healing.
The invention will be further described below by experiment.In experiment, method therefor is conventional method if no special instructions.
Extraction, purification and the determination of activity of the agglutinins such as experiment 1, Semen Phaseoli Vulgaris.
(1) to adopt application number be that 200910094233.1 the disclosed technology of Chinese patent file is carried out for the extraction of the agglutinin such as Semen Phaseoli Vulgaris and purification, and protein content adopts general biuret method to measure.
(2) measure to adopt application number be that 201110184061.4 the disclosed technology of Chinese patent file is carried out to activity of lectin.
(in vain) Semen Phaseoli Vulgaris phytohemagglutinin is made into 7 concentration experimental grouies of 0.1,0.2,0.5,1.0,2.0,5.0,10.0 mg/mL and 1 normal saline matched group.To contain variable concentrations Semen Phaseoli Vulgaris phytohemagglutinin filter paper (d=6 mm) with scraps of paper development method and be attached in the MRS solid medium that is coated with lactobacillus, 4 parallel group of each concentration is cultivated in 37 ℃ of constant incubators.Every 12 h observe a lactobacillus and breed situation and Taking Pictures recording, cultivate 72 h and finish.Repeated experiments three times.The impact of observation and analysis Semen Phaseoli Vulgaris phytohemagglutinin on lactobacillus propagation.
Cultivate with the MRS culture medium: adopt scraps of paper development method that tested material (the Semen Phaseoli Vulgaris phytohemagglutinin that is respective concentration is dissolved in the normal saline) filter paper (d=6 mm) that Semen Phaseoli Vulgaris phytohemagglutinin concentration is respectively 0.0,0.1,0.2,0.5,1.0,2.0,5.0,10.0 mg/mL is attached in 90 mm glass culture dishs of the MRS solid medium that scribbles lactobacillus, cultivate in 37 ℃ of constant incubators, wherein 0 mg/mL group is the blank group.Observe a lactobacillus every 12 h and breed situation and Taking Pictures recording result, cultivate 72 h and finish, analyze the Semen Phaseoli Vulgaris phytohemagglutinin to the impact of lactobacillus growth and propagation.Each experiment has 4 Duplicate Samples, the experiment triplicate.
After lactobacillus is cultivated 12 h, the filter paper that contains 1.0 mg/mL Semen Phaseoli Vulgaris phytohemagglutinin groups has a small amount of macrocolony to form on every side, and occur without obvious macrocolony around matched group and all the other each dosage group filter papers, show that 1.0 mg/mL Semen Phaseoli Vulgaris phytohemagglutinin groups have facilitation to lactobacillus growth and breeding at first.Fig. 1 is the microphotograph after lactobacillus is cultivated 12 h, expressing the Semen Phaseoli Vulgaris phytohemagglutinin of variable concentrations is matched group on the impact of lactobacillus growth: a, and b is 0.1 mg/mL group, and c is 0.5 mg/mL group, d is 1.0 mg/mL groups, and e is 5.0 mg/mL groups.
Experiment 3, Semen Phaseoli Vulgaris phytohemagglutinin are to the growth promoting function at body vagina lactobacillus
It is formulated that degree this test of agglutinin tested material is that the Semen Phaseoli Vulgaris phytohemagglutinin adds 3% tremella polysaccharide, and the content of Semen Phaseoli Vulgaris phytohemagglutinin is 40mg/ml; Tester is adjuvant, does not namely contain the tremella polysaccharide liquid of phytohemagglutinin.The pH value of phytohemagglutinin liquid and adjuvant is 4.5.
Experimental animal is 4 of Female rabbits, and body weight 2.0～2.5 kg divide equally cage and raise.20 ℃ of left and right of laboratory temperature.
Test basis: in Ministry of Public Health " disinfection technology standard, the third edition, the first fascicle, experimental technique standard " (version in 1999) the 3.8th.The method of inspection: PHA group, adjuvant matched group are set.To the animal label, 1 is matched group, and 2,3,4 are the PHA group, the sterilization cotton sliver that the PHA group is got suitable size soaks the tested material with 0.5ml, inserts in rabbit vagina, and the sterilization cotton sliver that the adjuvant matched group is got formed objects soaks with adjuvant, contact with vaginal mucosa, gave a medicine, continued medication 7 days in every 24 hours.
Getting rabbit vagina liquid before administration and cultivate observation in the MRS culture medium, is after administration finishes after 7 days, then gets the tested material group and matched group rabbit vagina liquid is cultivated observations in respectively at the MRS culture medium, comparison administration front and back vagina Flora dynamics.
Before administration, the bacterium colony adularescent yeast in culture medium and lactobacillus bacterium colony.After administration, be a large amount of lactobacilluss in culture medium corresponding to tested material group, and some lactobacilluss and yeast bacterium colony still occur in culture medium corresponding to adjuvant group.
Experiment 4, Semen Phaseoli Vulgaris phytohemagglutinin and red kidney bean phytohemagglutinin are on escherichia coli, staphylococcus aureus, beads pearl bacterium, saccharomycetic impact
Adopt respectively nutrient agar, the potato glucose culture medium, sabouraud culture medium is cultivated.Adopt conventional preparation, sterilization to make above-mentioned culture medium.Inoculate respectively escherichia coli, staphylococcus aureus, candidiasis, yeast.Place again the sterilization filter paper of diameter 6mm in plate, drip the Semen Phaseoli Vulgaris phytohemagglutinin of the filtration sterilization of variable concentrations on filter paper.Drip normal saline according to group.Be placed in 37 ℃ of couveuses and cultivate 36h.The results are shown in Table 1 and table 2.
The impact of table 1 Semen Phaseoli Vulgaris phytohemagglutinin on four kinds of bacterium
" 0 " expression has bacteriostasis."+" expression is without bacteriostasis.
The impact of table 2 red kidney bean phytohemagglutinin on four kinds of bacterium
" 0 " expression has bacteriostasis."+" expression is without bacteriostasis.
The impact on escherichia coli, staphylococcus aureus, yeast, beads pearl bacterium of experiment 5, the Semen Phaseoli Vulgaris that contains Chinese medicine ingredients and red kidney bean phytohemagglutinin coagulant liquid
The tested material formula that this experiment is used is as follows:
Contain following component in the 100ml coagulant liquid:
The Semen Phaseoli Vulgaris phytohemagglutinin is respectively 0.5 gram by high, medium and low concentration, 0.1 gram, and 0.05 gram and 0.01 gram, or the red kidney bean phytohemagglutinin is respectively 0.5 gram by high, medium and low concentration, 0.1 gram, and 0.05 gram and 0.01 gram,
Stachyose is or/and cottonseed sugar is respectively 2.0 grams,
Tremella polysaccharide 1.5 grams,
Bletilla glucomannan 0.2 gram,
The water extract of Radix Scutellariae dry powder 1.0 grams, Radix Berberidis dry powder 1.0 grams and Radix Sophorae Flavescentis dry powder 1.0 gram gained,
NaCl 0.9 gram,
PH buffer agent: be acetic acid-sodium-acetate buffer (pH4.5), get sodium acetate 1.8 grams, add glacial acetic acid 0.98ml, then be diluted with water to 100ml, and get final product.
Stabilizing agent: PEG 4,000 2.0 grams,
Antiseptic: potassium sorbate 0.3 gram.
PH is 0.45.
Experimental technique is with experiment 4.Adopt respectively nutrient agar, the potato glucose culture medium, sabouraud culture medium is to escherichia coli and staphylococcus aureus, and yeast and beads pearl bacterium are cultivated.
Adopt conventional preparation, sterilization makes above-mentioned culture medium.Inoculate respectively escherichia coli, staphylococcus aureus, candidiasis, yeast.Place again the sterilization filter paper of diameter 6mm in plate, drip Semen Phaseoli Vulgaris phytohemagglutinin and three kinds of coagulant liquids that Chinese medicine extract is mixed with of variable concentrations on filter paper.
Drip normal saline according to group.Be placed in 37 ℃ of couveuses and cultivate 36h.The results are shown in Table 3 and table 4.
Table 3 contains the Semen Phaseoli Vulgaris agglutinin coagulant liquid of Chinese medicine extract to the impact of four kinds of bacterium
Annotate: " 0 " expression has bacteriostasis.
Table 4 contains the red kidney bean agglutinin B gel of Chinese medicine extract to the impact of four kinds of bacterium
Annotate: " 0 " expression has bacteriostasis.
The concrete formula of medicinal liquid (coagulant liquid) is as follows:
Semen Phaseoli Vulgaris phytohemagglutinin 0.5 gram,
Tremella polysaccharide 2.0 grams,
Oligosaccharide (stachyose and cottonseed sugar) is 0.5g altogether,
Bletilla glucomannan 0.2 gram,
The water extract of Radix Scutellariae dry powder 1.0 grams, Radix Berberidis dry powder 1.0 grams and Radix Sophorae Flavescentis dry powder 1.0 gram gained,
The NaCl:0.85 gram,
PH buffer agent: be acetic acid-sodium-acetate buffer (pH4.5), get sodium acetate 1.8 grams, add glacial acetic acid 0.98ml, then be diluted with water to 100ml, and get final product.
Stabilizing agent: PEG 4,000 2.0 grams,
Antiseptic: potassium sorbate 0.3 gram.
PH value is 4.5.
" mycoplasma (Uu/Mh) the separation and Culture susceptibility test kit " that experiment adopts Zhuhai Dier Bioengineering Co., Ltd. to produce operates by operation instructions.At 37 ℃ of incubators cultivations 24 and 48h.Method sees the following form 5.
Table 5 culture medium and medicinal liquid scale
Positive inoculation liquid has namely infected mycoplasma and/or chlamydial culture fluid.
Step: get respectively the positive inoculation liquid of bottle 100 μ l, 20 μ l, 20 μ l, 20 μ l add respectively the culture medium of 390 μ l, 160 μ l, 120 μ l and 180 μ l by height in low and blank dosage, then add respectively 10 μ l, 20 μ l, 30 μ l and 0 μ l medicinal liquid to enter test tube.Add again approximately 1ml paraffin oil, cultivate in 37 degrees centigrade.
Result shows, observes through 24h, adds the low dosage medicinal liquid to fail to suppress or kill mycoplasma or chlamydia.And add middle and high dosage medicinal liquid can suppress or kill mycoplasma and/or chlamydia.To add again the taint-free culture fluid of middle and high dosage medicinal liquid to transfer in fresh culture after 48h, through 24h and 48h, until 72h observes the culture medium color without any variation.Therefore experimental result can illustrate that the middle and high dosage of coagulant liquid can kill mycoplasma.
Embodiment 1, formula A.Contain in 100 milliliters of coagulant liquids:
Semen Phaseoli Vulgaris phytohemagglutinin 0.5 gram,
Tremella polysaccharide 2.0 grams,
Oligosaccharide (total amount of stachyose and cottonseed sugar) 0.5g
Bletilla glucomannan 0.2 gram
NaCl 0.85 gram,
The pH buffer agent: be acetic acid-sodium-acetate buffer (pH4.5), get sodium acetate 1.8 grams, add glacial acetic acid 0.98ml, then be diluted with water to 100ml, and get final product,
Stabilizing agent: PEG 4,000 2.0 grams,
Antiseptic: potassium sorbate 0.3 gram,
PH value is 4.5.
0.5～2.0ml coagulant liquid adds water 100～200ml, can be used for the daily nursing of women's V﹠V is cleaned.Through the actual use of many people, reduce leucorrhea abnormal every day 1～2 time, eliminate the ill symptoms successfuls such as abnormal flavour and pruritus.
Phytohemagglutinin 0.5 gram,
Tremella polysaccharide 2.0 grams,
Oligosaccharide (total amount of stachyose and cottonseed sugar) 0.5g,
Bletilla glucomannan 0.2 gram,
Each 1.0 grams of Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder, the water extract of totally 3.0 gram gained,
NaCl 0.85 gram,
PH buffer agent: citric acid-sodium hydrogen phosphate buffer (pH4.0).First liquid: get citric acid 21g or anhydrous citric acid 19.2g, add water and make and be dissolved into 1000ml, put in refrigerator and preserve.Second liquid: get sodium hydrogen phosphate 71.63g, add water and make and be dissolved into 1000ml. and get above-mentioned first liquid 61.45ml and mix with second liquid 38.55ml, shake up, and get final product,
Stabilizing agent: mannose 3.0 grams,
Antiseptic: ethyl ester sodium 0.15 gram,
PH value is 4.5-4.7.
Embodiment 3, to the treatment of vagina
Press the A formula of embodiment 1, when vagina occurs, by each 2～3ml, inject vagina.Every day 1～2 time.It is more than therapeutic dose.Observe after 48 hours, if the Shi Zeying that is not clearly better adopts the formula B of embodiment 2.Therapeutic effect to vagina is satisfied.
Embodiment 4, to mycoplasma or chlamydial treatment
When medical diagnosis is defined as woman vagina or pudendum mycoplasma or chlamydia infection, or the vagina that causes of other reason, process when not improving after 48 hours through the formula A of embodiment 1, can adopt embodiment 2 formula B to process.Consumption is every day 2～3 times, each 3～5mL.Use continuously after 3～7 days, through statistical analysis, effective percentage 100%, obvious effective rate 82%, cure rate 65～70%.
Embodiment 5, to the HPV(human papillomavirus) therapeutical effect
The patient revives so-and-so, female, 25 years old.Symptom is that pudendum is the black pathological changes, and pruritus, vaginal secretions are the thickness sample, and cervix uteri is smooth.Getting secretions send " golden territory inspection body " to test.Related check report explanation: " second filial generation hybrid capture technology (HC2) of this experiment employing drugs approved by FDA can detect 16,18,31,33,35,39,45,51,52,56,58,68 totally 13 kinds of high-risk hypotype HPV simultaneously ".Positive (the result (test ratio=3600(reference value is normal ratio＜1.00) of assay: HPV-DNA.Diagnosis: HPV infects (positive).
Treatment: give interleukin 6 0IU intramuscular injection, biweekly.Vagina gives gel B and the interferon suppository of embodiment 2, is used alternatingly.Gel B consumption is every day 2～3 times, each 3～5ml, and administration is 5 days weekly.After three weeks, the pruritus vulvae symptoms are alleviated, and (leep knife) treatment of performing the operation of external dark and gloomy color lesion continues vagina administration subsequently, takes valaciclovir check afterwards in 27 days after 6 weeks, and the HPV-DNA value is reduced to 366.Continue to use gel B surrounding, the HPV-DNA value detects negative (being reduced to 0.1).Rehabilitation.
The patient: model so-and-so, man, 55 years old.At the beginning of 2012 4 months, slap the back side owing to toiling away at the right hand and begin to occur blister shape herpes, the about 6cm of area
2,After about 10 days, herpes begins to break and trickle, follows pain.Then hospital treatment, be admitted to hospital 10 days, and intravenous injection and antiviral agents for oral use such as acyclovir add and smear interferon.Continue to smear interferon after leaving hospital, use 10 after effect still bad.Then use the gel B of similar embodiment 2 instead, distinguish as without the Radix Sophorae Flavescentis composition, the amount of Radix Scutellariae and Radix Berberidis water extract changes the water extract of dry powder 1.5 grams separately into.Use this gel to smear.Every day 4～5 times, each approximately 1.0ml.Use 10 days left and right herpess namely to fully recover, painless.Compare with interferon, this gel curative effect is obvious, and analgesic effect is arranged.
Embodiment 7, to the effect of general traumatic injury of skin
To skin and the muscle injury of common mechanical, as wound foreign etc., can directly use the B component gel that contains PHA.With embodiment 7.Have rapid hemostasis, protect from infection and the effect of accelerating wound.But contrast positive drug matched group accelerating wound speed approximately 3 days.
The scalding model of skin: select 24 S-129 mices, remove after anesthesia the both sides, back apart from spinal column 5mm place the about hair-fields of 20mm * 20mm, with temperature about 120 ℃ in the centre of hair-fields, the diameter of perming is the electrinic iron flicking 6 seconds of 10mm, causes the II degree to scald.(Liu Yi, Su Zhihong. the impact [J] of EGF on the dark II degree of mice scalding model wound healing. Beijing Military Area Command's medicine. 2000,12(6); Zhong Weitian, Hua He and, Zhong Xiwen. quick-acting burn cream is scalded the therapeutical effect [J] of Cavia porcellus to dark II degree. China's burn magazine. 2006,22(4) .).
Process: one group of wound is used with another group wound of A component Semen Phaseoli Vulgaris phytohemagglutinin solution erasing (experimental group) of embodiment 1 with YUNNAN BAIYAO solution erasing (matched group), the 3rd group of wound do not deal with (blank group), characteristics due to the mice life habit, all wounds are not wrapping all, smear medicine once to wound every day, discontinues medication when having wound to begin desquamation.
The wound surface situation of change: tested the 2nd day, the burnt white tissue of respectively forming face disappears, and becomes redness.The 3rd day, the face of respectively forming showed and all is peony, and forms the very hard thick shell of one deck on its surface.The 4th day, respectively form the face complexion changed black, test group and matched group begin to occur healing state.The 5th day, the duricrust edge perk of the most of wound surface of test group.The 7th day, the duricrust of most of wound surface of test group came off, and formed the softer shell of one deck in wound surface, and the shell of matched group and blank group wound surface is still very hard very thick.The 13rd day, the wound of experimental group and matched group healed basically, and the wound of blank group is also not healing all.The 15th day, the wound of experimental group and matched group is all healed, and the wound of blank group is also no healing all.The wound surface diameter measurement the results are shown in Table 6.
The wound surface diameter of different number of days after table 6 scald group wound
Processed through spss 11.5 by table 2 data, the p=0.043 ﹤ 0.05 of experimental group and matched group illustrates significant difference; The p=0.026 ﹤ 0.05 of experimental group and blank group illustrates significant difference.
As shown in Figure 2, three groups of effects to scalding healing are respectively experimental group〉matched group〉blank group, illustrate that thus the Semen Phaseoli Vulgaris phytohemagglutinin has obvious facilitation to the healing of scalding.
Claims (4)
1. the application of Semen Phaseoli Vulgaris phytohemagglutinin in preparation human medicine is characterized in that: with the Semen Phaseoli Vulgaris phytohemagglutinin as active component for the preparation of the medicine that increases lactobacillus quantity in woman vagina.
2. pharmaceutical composition is characterized in that:
Take Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan as active component, relative weight share between active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan;
Or take Semen Phaseoli Vulgaris phytohemagglutinin, tremella polysaccharide, stachyose or/and cottonseed sugar, Bletilla glucomannan, Radix Scutellariae extract, Radix Berberidis extract, Radix Sophorae Flavescentis extract as active component, relative weight share between active component is: 0.5～1.0 part of Semen Phaseoli Vulgaris phytohemagglutinin, 1.5～3.0 parts of tremella polysaccharides, stachyose is or/and 0.2～2.0 part of cottonseed sugar, 0.2～0.5 part of Bletilla glucomannan, one or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder are the extract of totally 1.0～3.0 parts of gained.
3. pharmaceutical composition as claimed in claim 2, it is characterized in that: the extract of Radix Scutellariae, Radix Berberidis and Radix Sophorae Flavescentis dry powder gained is the extract that water extraction produces.
4. pharmaceutical composition as claimed in claim 2, is characterized in that being gel, contains following component in every 100ml coagulant liquid:
Semen Phaseoli Vulgaris phytohemagglutinin 0.5～1.0 gram,
Tremella polysaccharide 1.5～3.0 grams,
Stachyose is or/and cottonseed sugar 0.5～2.0 gram,
Bletilla glucomannan 0.2～0.5 gram,
NaCl 0.8～0.9 gram,
The pH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically;
Or contain following component in every 100ml coagulant liquid:
Semen Phaseoli Vulgaris phytohemagglutinin 0.5～1.0 gram,
Tremella polysaccharide 1.5～3.0 grams,
Stachyose is or/and cottonseed sugar 0.5～2.0 gram,
Bletilla glucomannan 0.2～0.5 gram,
One or more in Radix Scutellariae dry powder, Radix Berberidis dry powder and Radix Sophorae Flavescentis dry powder are water extract of totally 1.0～3.0 gram gained,
NaCl 0.8～0.9 gram,
The pH buffer agent is coagulant liquid acceptable amount pharmaceutically,
Stabilizing agent is coagulant liquid acceptable amount pharmaceutically,
Antiseptic is coagulant liquid acceptable amount pharmaceutically.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056588.8A CN103157095B (en) | 2013-02-22 | 2013-02-22 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310056588.8A CN103157095B (en) | 2013-02-22 | 2013-02-22 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103157095A true CN103157095A (en) | 2013-06-19 |
| CN103157095B CN103157095B (en) | 2014-09-17 |
Family
ID=48580960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310056588.8A Active CN103157095B (en) | 2013-02-22 | 2013-02-22 | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103157095B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920140A (en) * | 2014-05-04 | 2014-07-16 | 云南康洲生物科技有限公司 | Compound preparation for reducing blood glucose, body weight and fat for human |
| CN107213453A (en) * | 2017-06-21 | 2017-09-29 | 云南康洲生物科技有限公司 | A kind of abortifacient |
| CN108404111A (en) * | 2017-12-25 | 2018-08-17 | 云南康洲生物科技有限公司 | One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component |
| CN109674671A (en) * | 2019-01-07 | 2019-04-26 | 广州市拓瑞科技有限公司 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
| CN110755601A (en) * | 2019-10-31 | 2020-02-07 | 云南康洲生物科技有限公司 | Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof |
| CN111450235A (en) * | 2020-06-05 | 2020-07-28 | 杨正东 | Contraceptive gel jelly |
-
2013
- 2013-02-22 CN CN201310056588.8A patent/CN103157095B/en active Active
Non-Patent Citations (3)
| Title |
|---|
| 殷晓丽等: "豆科凝集素研究进展", 《中国生物工程杂志》 * |
| 王军等: "从大白芸豆种子中分离与表征一种新型凝集素WKBL", 《中国生物化学与分子生物学报》 * |
| 陈元坤等: "植物血凝素在防控畜禽疾病中的应用", 《兽医导刊》 * |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103920140A (en) * | 2014-05-04 | 2014-07-16 | 云南康洲生物科技有限公司 | Compound preparation for reducing blood glucose, body weight and fat for human |
| CN103920140B (en) * | 2014-05-04 | 2016-06-08 | 云南康洲生物科技有限公司 | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation |
| CN107213453A (en) * | 2017-06-21 | 2017-09-29 | 云南康洲生物科技有限公司 | A kind of abortifacient |
| WO2018233509A1 (en) * | 2017-06-21 | 2018-12-27 | 云南康洲生物科技有限公司 | Abortion drug |
| CN107213453B (en) * | 2017-06-21 | 2020-07-14 | 云南康洲生物科技有限公司 | Abortion medicine |
| US11219655B2 (en) | 2017-06-21 | 2022-01-11 | Yunnan Kang-Zhou Biotech Co., Ltd. | Abortion medications and administration method thereof |
| CN108404111A (en) * | 2017-12-25 | 2018-08-17 | 云南康洲生物科技有限公司 | One kind is with kidney bean phytolectin inhibitory anti-virus preparation as main component |
| CN108404111B (en) * | 2017-12-25 | 2020-04-28 | 云南康洲生物科技有限公司 | A bacteriostatic and antiviral preparation containing semen Phaseoli vulgaris phytohemagglutinin as main ingredient |
| CN109674671A (en) * | 2019-01-07 | 2019-04-26 | 广州市拓瑞科技有限公司 | The preparation method of vaginal care composition object and its application and the women secret conditioning liquid comprising it and women secret conditioning liquid |
| CN110755601A (en) * | 2019-10-31 | 2020-02-07 | 云南康洲生物科技有限公司 | Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof |
| CN111450235A (en) * | 2020-06-05 | 2020-07-28 | 杨正东 | Contraceptive gel jelly |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103157095B (en) | 2014-09-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2609754C (en) | Compositions of benzoic acid and saccharides for regulating and maintaining bacterial flora and acidity in the vagina | |
| CN103157095B (en) | Kidney bean phytolectin applications in preparation of human drugs and drug composition thereof | |
| CN1251763A (en) | Process for preparing Chinese medicine 'Qianjin tablets' for treating gynopathy | |
| CN109985069B (en) | Probiotic compositions and uses thereof | |
| CN102727531A (en) | Active lactic acid bacteria capsules with treatment and prevention effect on vaginitis | |
| CN108611295B (en) | Bacteroides fragilis for relieving endotoxin infection and application thereof | |
| CN101797269B (en) | Physiological balance liquid for adjusting microecology in vaginas of women | |
| CN113274414A (en) | Probiotics preparation for repairing and maintaining vaginal microecological balance | |
| CN101690734B (en) | Lactobacillus vaginal capsule and preparation method thereof | |
| CN103520262B (en) | A kind of lipid soluble gynecological gel | |
| CN109771595A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gynaecological imflammation | |
| CN103599437B (en) | One treats colpitic traditional Chinese medicine liquid | |
| CN103251845B (en) | For the compositions of cleaning throat and moistening larynx | |
| CN106581172B (en) | Medicine for preventing and treating mycotic vaginitis, trichomonas vaginitis and senile vaginitis and preparation method thereof | |
| CN111759852A (en) | Pharmaceutical composition for vagina, pharmaceutical preparation, preparation method and application thereof | |
| CN108785383A (en) | A kind of antibacterial gynecology externally used pharmaceutical combination and the preparation method and application thereof | |
| CN104208194B (en) | Traditional Chinese medicine composition for treating bovine endometritis, preparation method and application thereof | |
| CN102743471B (en) | Lignum et Radix Naucleae extract and the treatment use to pelvic inflammatory disease thereof | |
| CN107080817A (en) | A kind of Novel gynecology-department a thousand pieces of gold oil of zedoary turmeric bolt | |
| CN101554407A (en) | Shuanghuanglian soluble powder preparation technique and application thereof | |
| CN107837274A (en) | A kind of purposes of diet fiber composition | |
| CN105125990A (en) | Traditional Chinese medicine gel for promoting wound healing in lateral perineotomy | |
| CN105079482B (en) | A kind of Chinese medicine external gel treating the companion's infection of serious decubital ulcer and preparation method thereof | |
| CN105106475A (en) | Traditional Chinese medicine gel used for treating toxin-accumulating rotting and ulcerating type bedsores during clinical nursing | |
| CN115873777A (en) | Oriented domestication modified probiotics, microecological preparation containing probiotics and application of probiotics in gynecological inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |